[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sacubitrilvalsartan\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sacubitrilvalsartan":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,78,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100607729","sacubitrilvalsartan-in-patients-with-prosthetic-heart-valves-with-heart-failure-and-reduced-ejection-fraction-100607729",false,"NCT07192341","Sacubitril\u002FValsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction","Effect of Sacubitril\u002FValsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* Both sexes.\n* Patients with a history of prosthetic heart valves.\n* Patients diagnosed with heart failure with reduced ejection fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) ≤ 40% with New York Heart Association (NYHA) functional class II-IV.\n\nExclusion Criteria:\n\n* Hemodynamic instability.\n* Use of a circulatory auxiliary circulation device.\n* Severe hepatic \\[alanine aminotransferase (ALT) \\>120 U\u002FL\\] and renal insufficiency \\[estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\\].\n* Blood pressure \\\u003C100\u002F60 mmHg.\n* Serum potassium \\>5.3 mmol\u002FL.\n* Severe pulmonary hypertension.\n* Malignant arrhythmia.\n* Malignant tumor.\n* Known history of hereditary or primary angioedema.\n* Serious adverse drug reactions or serious complications over the course of treatment.","ALL","18 Years",{"count":19,"type":20},220,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to evaluate the effect of sacubitril\u002Fvalsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).",[26,27,28,29],"Sacubitril\u002FValsartan","Prosthetic Heart Valve","Heart Failure","Reduced Ejection Fraction","RECRUITING","2025-09-27",{"date":33,"type":34},"2025-09-30","ACTUAL",{"date":31,"type":34},{"date":37,"type":20},"2026-02-01",{"name":39,"class":40},"Kafrelsheikh University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100585318","evaluating-dashboard-integrated-pharmacist-led-education-on-improving-sacubitrilvalsartan-adherence-in-heart-failure-pharmd-assist-hfref-100585318","NCT06900803","Evaluating Dashboard-Integrated Pharmacist-Led Education on Improving Sacubitril\u002FValsartan Adherence in Heart Failure (PharmD ASSIST HFrEF)","Pharmacist-Led Education Through Interactive Visualization Dashboards for Adherence Support and Sustained Involvement in Sacubitril\u002FValsartan Therapy for Patients With Heart Failure With Reduced Ejection Fraction (PharmD ASSIST HFrEF): Study Protocol for Implementation in a Parallel-Group, Pragmatic Randomized Controlled Trial","Inclusion Criteria:\n\n* adults aged 20 or older\n* a diagnosis of HFrEF, which is defined by a left ventricular ejection fraction of 40% or less\n* currently receiving sacubitril\u002Fvalsartan at the time of recruitment\n* receiving care at the cardiology department or cardiology ward at National Taiwan University Hospital\n* referral from the clinicians at National Taiwan University Hospital\n\nExclusion Criteria:\n\n* unable or unwilling to provide informed consent, adhere to study protocols, or complete required questionnaires in person during three scheduled visits (i.e., 3, 6, 12 months after the baseline measurement)\n* having received care at the pharmacist-led HF clinic at National Taiwan University Hospital","20 Years",{"count":51,"type":20},200,[23],"The goal of this pragmatic clinical trial is to evaluate whether pharmacist-led education, integrated with interactive visualization dashboards, can enhance medication adherence in patients with heart failure who are prescribed sacubitril\u002Fvalsartan. The main question it aims to answer is: Can pharmacist-led interactive visualization dashboards improve adherence to sacubitril\u002Fvalsartan compared to usual care without the dashboard intervention?\n\nResearchers will compare patients receiving pharmacist-led education with interactive dashboards to those receiving standard education, assessing differences in medication adherence and clinical outcomes, among others.\n\nParticipants will:\n\n* Complete baseline and follow-up questionnaires on medication adherence and satisfaction with pharmacist-provided services, and others.\n* Engage in education sessions led by pharmacists, with or without dashboard integration.\n\nThe study outcomes will include medication adherence, and secondary outcomes such as patient satisfaction with pharmacist-provided services, optimized guideline-directed medical therapy score, time to high medication adherence, the calculated proportion of days covered, New York Heart Association functional classification, and the net promoter score used for evaluating recommendation and satisfaction with the dashboard intervention.",[55,26,56],"Heart Failure With Reduced Ejection Fraction (HFrEF)","Medication Adherence",[58,59,60,61,62,63,64,65,66,67],"heart failure with reduced ejection fraction","medication adherence","dashboard","health information technology","patient education","pharmacist","pragmatic trial","randomized controlled trial","sacubitril\u002Fvalsartan","implementation","NOT_YET_RECRUITING","2025-03-27",{"date":71,"type":34},"2025-04-02",{"date":73,"type":20},"2025-04-07",{"date":75,"type":20},"2027-10-31",{"name":77,"class":40},"National Taiwan University Hospital",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":85,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":90,"conditions":91,"keywords":103,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":5},"100474986","phase-4-sacubitrilvalsartan-in-primary-prevention-of-the-cardiotoxicity-of-systematic-breast-cancer-treatment-mainstream-100474986","NCT05465031","Sacubitril\u002FValsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)","Sacubitril\u002FValsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent","Inclusion Criteria:\n\n* Written informed consent\n* Female gender, aged 18 years and over\n* Patients with histologically confirmed breast cancer and complete assessment of tumor phenotype (Estrogen receptor - ER, Progesterone receptor - PR, Human epidermal growth factor receptor 2 - HER2, Kiel - Ki67)\n* Ability to take oral medication and willingness to adhere to the planned regimen\n* Tumor grade IA-IIIC or oligometastatic grade IV\n* Radical treatment plan including surgery\n* Plan of use of systemic treatment (preoperative, postoperative or combined) with anthracyclines and\u002For anti-HER2 drugs\n* Eastern Cooperative Oncology Group (ECOG) 0-2 general status\n* LVEF ≥ 50% as assessed by echocardiography\n* Sinus rhythm\n\nExclusion Criteria:\n\n* Prior anthracycline-based chemotherapy and\u002For thoracic radiotherapy (prior to diagnosis of the cancer being the present cause of therapy)\n* Clinically relevant HF (NYHA II-IV)\n* Myocardial infarction (MI) within the last \\\u003C 3 months\n* Symptomatic hypotension or systolic blood pressure (SBP) \\\u003C 90 mmHg\n* Significant valvular disease, symptomatic coronary artery disease (CCS\\>2), significant atrioventricular (AV) block, symptomatic sinus node dysfunction\n* Expected survival \\\u003C12 months\n* Glomerular filtration rate (GFR) \\\u003C30 ml\u002Fmin\u002F1.73 m2 (screening visit)\n* K+\\>5.5mmol\u002FL (screening visit)\n* Contraindications to angiotensin converting enzyme inhibitor (ACE-I)\u002Fangiotensin II receptor blocker (ARB) or LCZ696 if not listed among criteria\n* Active untreated liver disease\n* Pregnancy\n* Conditions\u002Fcircumstances that may lead to non-compliance with medical staff recommendations (e.g. active drug\u002Falcohol dependence, poorly controlled mental illness)","FEMALE",{"count":87,"type":20},600,[89],"PHASE4","Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more than 2.25 million new cases of breast cancer in women in 2020. Although the modern treatment strategies, based on the complex care, which consists of surgery, radiotherapy, hormone therapy, and targeted chemotherapy directed at specific cancer molecules have substantially reduced the risk of death due to breast cancer, their wide adoption results in the wider prevalence of cardiotoxicity, defined as either symptomatic heart failure, or asymptomatic contractile dysfunction. The occurrence of cardiotoxicity induced by anti-cancer therapies is estimated at 5-15%, and its development is the primary cause of therapy termination, which significantly reduces the probability of the efficacy of treatment. Several attempts have been made to determine the efficacious preventive strategy, which could diminish the risk of cancer-therapy induced cardiotoxicity. The results of the prior studies indicated a trend towards lower risk of troponin elevation, or left ventricular contractile dysfunction with the introduction of drugs interfering with the renin-angiotensin-aldosterone (RAA) axis, which constitute the primary treatment modality in heart failure with reduced ejection fraction (HFrEF). Sacubitril\u002Fvalsartan, the novel therapeutic agent, has been demonstrated to significantly improve prognosis in patients with HFrEF. Prior retrospective, small, single-center studies have shown that treatment with sacubitril\u002Fvalsartan may reduce the risk of cancer-therapy induced cardiotoxicity, or reverse contractile dysfunction caused by anti-cancer therapy. However, no large randomized data confirmed these findings.\n\nTherefore, the Sacubitril\u002FValsartan in PriMAry preventIoN of the cardiotoxicity of systematic breaST canceR trEAtMent) study, has been designed to verify, whether the preventive use of sacubitril\u002Fvalsartan administered in the doses recommended in patients with HFrEF in breast cancer patients undergoing adjuvant chemotherapy with anthracyclines or anthracyclines and HER-2 monoclonal antibodies, will reduce the incidence of cardiotoxicity defined as impaired left ventricular systolic function on transthoracic echocardiography (TTE). In the trial, a total of 480 patients with histologically confirmed breast cancer, who are eligible for chemotherapy with anthracyclines or anthracyclines and HER-2 monoclonal antibodies, will undergo 1:1 randomization to either preventive treatment with sacubitril\u002Fvalsartan or placebo. The patients will be followed for 24 months, and will have repetitive efficacy and safety examinations, including echocardiography, MRI (optionally), electrocardiography including 24-h Holter monitoring, blood tests, functional capacity tests and quality of life assessment.",[92,93,94,95,26,96,97,98,28,99,100,101,102],"Breast Cancer","Neoplasm, Breast","Breast Diseases","Antihypertensive Agents","Angiotensin II Type 1 Receptor Blockers","Angiotensin Receptor Antagonists","Molecular Mechanisms of Pharmacological Action","Cardiac Toxicity","Cancer, Therapy-Related","Cancer Therapy-Related Cardiac Dysfunction","Cardiotoxicity",[104,26,105,106,107,92,102,108,109,110,111],"LCZ696","Magnetic Resonance Imaging","Echocardiography","Cardio-oncology","Anthracyclines","Trastuzumab","Heart failure","Cardioprotection","2025-03-11",{"date":114,"type":34},"2025-03-14",{"date":116,"type":34},"2024-04-17",{"date":118,"type":20},"2029-02",{"name":120,"class":40},"Silesian Centre for Heart Diseases",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":41},"100477569","effect-of-sacubitrilvalsartan-on-cardiac-function-in-hypertensive-patients-stratified-by-bmi-a-real-world-study-100477569","NCT05498675","Effect of Sacubitril\u002FValsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","Effect of Sacubitril\u002FValsartan on Cardiac Function Assessed by Cardiac Magnetic Resonance (CMR) in Hypertensive Patients Stratified by Body Mass Index (BMI): A Real World Study","Inclusion Criteria:\n\n* Patients with essential hypertension\n* 18-70 years old\n* No major barriers to provide written consent\n\nExclusion Criteria:\n\n* Secondary hypertension, except because of sleep apnea\n* cardiovascular disease (myocardial infarction, heart failure, stroke or coronary revascularization) within 6 months\n* Severe concomitant diseases (autoimmune disease, malignancy, late stage of liver diseases, respiratory diseases and digestive diseases)\n* Unable to understand or comply with the study procedures","70 Years",{"count":130,"type":20},180,"OBSERVATIONAL","The purpose of this study is to investigate the effect of sacubitril\u002Fvalsartan on cardiac function assessed by cardiac magnetic resonance (CMR) in hypertensive patients stratified by BMI.",[26,134,135],"Hypertension","Obesity",[137,138],"Cardiac function","Cardiac magnetic resonance","2025-02-11",{"date":141,"type":34},"2025-02-13",{"date":143,"type":34},"2021-09-01",{"date":145,"type":20},"2027-06-30",{"name":147,"class":40},"Beijing Friendship Hospital"]